TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01602003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444 25mg bid
Description: Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC15-0444 50mg qd
Description: Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg qd
Description: Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
Study: NCT02788617

Intervention type: DEVICE
Intervention: Diafert
Description: The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
Study: NCT01213615

Intervention type: DEVICE
Intervention: Valve replacement
Description: Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
Study: NCT03334773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Study: NCT02384083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filanesib, pomalidomide and dexamethasone
Description: Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
Study: NCT01580007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Sodium Phenylbutyrate and active cholecalciferol
Description: Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Sodium Phenylbutyrate plus active cholecalciferol
Description: Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Sodium Phenylbutyrate and placebo cholecalciferol
Description: Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sodium Phenylbutyrate plus placebo cholecalciferol
Description: Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
Study: NCT00525811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient dialogue
Description: Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient information
Description: Information on acute low back pain, information on depression
Study: NCT01904292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Subcutaneous 162 mg dose QW or Q2W for 52 weeks
Study: NCT03580408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastin
Description: 6mg/m²
Study: NCT00593710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan (25mg OD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol (25-50mg OD)
Study: NCT00419653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study: NCT05562583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAGE LEAF
Description: SAGE LEAF covers 8 skills and each skill has related home-practice activities that unlock every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time.
Study: NCT00178932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genetic analysis
Description: genetic assay of blood sample drawn with patient's consent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genetic analysis
Description: genetic assay of blood sample drawn with patient's consent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genetic assay
Description: genetic assay of blood sample drawn with patient's consent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genetic assay
Description: genetic assay of blood sample drawn with patient's consent
Study: NCT01748422

Intervention type: DRUG
Intervention: Qutenza
Description: Transdermal patch
Study: NCT04979195

Intervention type: OTHER
Intervention: Patients with stable normal kidney function
Description: Covid-19 patients with stable kidney function will represent group 1.

Intervention type: OTHER
Intervention: Patients with stable normal kidney function
Description: Covid-19 patients with stable kidney function will represent group 1.

Intervention type: OTHER
Intervention: Patients with unstable kidney function
Description: Covid-19 patients with unstable kidney function will represent group 2.

Intervention type: OTHER
Intervention: Patients with unstable kidney function
Description: Covid-19 patients with unstable kidney function will represent group 2.
Study: NCT04569422

Intervention type: DRUG
Intervention: Benoxyl
Description: reduce pain
Study: NCT03942068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
Study: NCT03928756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push Notifications with Tailored Intervention Content
Description: Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push Notifications with Engaging, Non-therapeutic Content
Description: Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Push Notifications
Description: Participants will not receive a push notification.
Study: NCT03831412

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
Study: NCT00419653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Study: NCT02951559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Brushing
Description: Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril.
Study: NCT02340754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MS Education Control
Study: NCT01474460

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phytonadione
Description: Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
Study: NCT03831412

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERRT
Description: Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
Study: NCT01712165

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ANMUM Materna

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (milk powder)
Study: NCT04283682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early skin-to-skin combined with breast-feeding
Description: Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
Study: NCT02619110

Intervention type: OTHER
Group type: OTHER
Intervention: backward walking treadmill training
Description: subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional physical therapy
Description: subjects accepted 30 minutes traditional physical therapy three times a week for four weeks

Intervention type: OTHER
Group type: OTHER
Intervention: conventional physical therapy
Description: subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
Study: NCT03699462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma solution-A injection
Description: The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Albumin
Description: The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
Study: NCT00707278

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
Study: NCT02074969

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Nail 3
Description: Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA
Description: Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
Study: NCT02777970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride/Dexketoprofen Trometamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Hydrochloride/Paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT01194531

Intervention type: DEVICE
Group type: OTHER
Intervention: 24 Chromosome Aneuploidy Screening with Parental Support
Description: Preimplantation Genetic Screening (PGS)
Study: NCT02900105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg (1 tablet) once a day for 4 months
Study: NCT01008956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
Description: Intramuscular injection, one dose
Study: NCT01328106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Repeating oral dose
Study: NCT00759785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab (MK0646)
Description: Single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab (MK0646)
Description: Single intravenous infusion
Study: NCT03030144

Intervention type: OTHER
Group type: OTHER
Intervention: Evidence based nursing recommendations
Description: The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
Study: NCT02149823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 24 Intranasal Units (IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 24 Intranasal Units (IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 24 Intranasal Units (IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 40 Intranasal Units (IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 40 Intranasal Units (IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 40 Intranasal Units (IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 40 Intranasal Units (IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon 40 Intranasal Units (IU)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Placebo
Study: NCT01785511

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: UVA Radiation
Description: UVA radiation exposure for 20 minutes

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVA Radiation
Description: UVA radiation exposure for 20 minutes
Study: NCT03976167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen administration with Common nasal cannula
Description: Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel
Study: NCT00915486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Good Standard of Care (GSoC)
Description: Procedural treatment twice per week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Good Standard of Care (GSoC)
Description: Procedural treatment twice per week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Good Standard of Care (GSoC)
Description: Procedural treatment twice per week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Good Standard of Care (GSoC)
Description: Procedural treatment twice per week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Good Standard of Care (GSoC)
Description: Procedural treatment twice per week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Topical fibrin as an adjunct to GSoC twice per week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-020201
Description: Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-020201
Description: Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: I-020201
Description: Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
Study: NCT04809857

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT03047720

Intervention type: DEVICE
Group type: OTHER
Intervention: Lully Sleep Guardian
Description: In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lully Sleep Guardian
Description: In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study.
Study: NCT01099501

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
Description: Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oxepa
Description: A dose determined by a patient's energy expenditure and tolerance of enteral feeding.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
Study: NCT00226668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCRF
Description: hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo hCRF
Description: placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
Study: NCT04497870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peppermint oil
Description: Administration of peppermint oil at one of two daily doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Description: Administration of peppermint oil at one of two daily doses.
Study: NCT02002039

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erythropoietin
Description: 500 units /kg /day every other day for 5 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: 500 units /kg /day every other day for 5 doses
Study: NCT01474460

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytonadione
Description: Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
Study: NCT03350243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCENT Intervention
Description: 1. Acceptance and Commitment Therapy approach: engaging families through structured individual or group sessions within the NICU and continue this support once discharged.~2. Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~3. Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support.
Study: NCT01627080

Intervention type: OTHER
Intervention: Cardiac Biomarker Blood Draws
Description: Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
Study: NCT00350701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgel
Description: androgel 5g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgel 10g
Description: androgel 10g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03145467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
Study: NCT02276391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/HCTZ combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan